Rapid HIV‐1 genotyping assay for the detection of capsid mutations

Abstract

AbstractHuman immunodeficiency virus (HIV) capsid is one of the most recent viral proteins successfully targeted for the development of antiretrovirals. Lenacapavir is a first in class HIV‐1 capsid inhibitor that was recently approved for the treatment of highly treatment‐experienced people with HIV in combination with other anti‐HIV drugs. Owing to the novelty of the viral target, methods to characterize the potential resistance‐associated mutations present in capsid upon treatment failure have not been fully established yet. Here, we describe a rapid and simple method to amplify capsid fragments and to determine their sequence from various clinical samples including diverse HIV‐1 subtypes. These methods could easily be implemented in laboratories, including hospital laboratories often caring for this patient population.